Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the second quarter of 2010 on Thursday, August 5, 2010. A press release announcing the results is scheduled for release after the close of trading.

Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of B. Melina Cimler, Ph.D., as Vice President, Quality and Regulatory Affairs, reporting to Christian Henry, Senior Vice President, Chief Financial Officer and General Manager, Life Sciences. Dr. Cimler will lead Illumina’s quality and regulatory organizations to support the development, manufacture and distribution of products serving the research, consumer and molecular diagnostic markets.

Merck KGaA*, a global pharmaceutical and chemical company, today announced the successful completion of its acquisition of Millipore Corporation (formerly NYSE: MIL), a leading Life Science company based in Billerica, Massachusetts, USA, for an aggregate purchase price including debt and cash of approximately $7.0 billion. Merck agreed to acquire Millipore on February 28, 2010 for $107 in cash per share of Millipore common stock.

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2010 following the close of market on Tuesday, July 27, 2010.

On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time) Jay Flatley, president and chief executive officer, and Christian Henry, senior vice president, chief financial officer and general manager, Life Sciences, will host a conference call with analysts, investors and other interested parties to discuss financial and operating results.

Utilizing Fluidigm Corporation’s Dynamic Array™ and Digital Array™ integrated fluidic circuits (IFCs), Stanford University researchers to have discovered a much larger spectrum of differences between individual cells than has previously been demonstrated. Among these differences are the communication capabilities that emerge from the interactions of genetic circuitry that mediates cell-to-cell communication.

Ariadne announces that Takeda San Francisco, Takeda’s global center for excellence for biologics, has signed an agreement to license Ariadne’s Pathway Studio® software. Takeda plans to utilize the software and underlying text-mining algorithms in their discovery program against cancer, inflammatory and metabolic diseases.

Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States. The LightCycler MRSA Advanced Test is a qualitative in-vitro diagnostic test for the direct detection of nasal colonization with bacterial MRSA, and it is designed to aid in the prevention and control of MRSA infections in healthcare settings. Roche’s new real-time polymerase chain reaction (PCR) test delivers rapid results (within two hours) and appears to have better sensitivity compared to direct culture-based methods.

Affymetrix, Inc. (Nasdaq:AFFX) today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2010 to be in the range of $71-72 million, as compared to the Company’s previous guidance in the range of $80-82 million. The company expects product revenue for the second quarter of 2010 to be approximately $65-66 million, including instrument sales of approximately $4-5 million and consumable sales of approximately $60-61 million.

Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore’s purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.

Illumina, Inc. (NASDAQ:ILMN) today announced that Gerald Möller, Ph.D., has joined the company’s Board of Directors. Dr. Möller is currently an advisor at HBM Bio Ventures AG, a Swiss investment firm focusing on biotechnology, emerging pharma, medical technology and related industries.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 1 million supports MorphoSys in accelerating the development of its HuCAL-based cancer program MOR202 into clinical development for the treatment of multiple myeloma. As part of the program, the Company plans to explore relevant biomarkers for the anti-CD38 approach in collaboration with Klinikum rechts der Isar, the university hospital of Munich Technical University.

Protagen AG, Dortmund, and the Neuried, Germany, based diagnostics company Mikrogen GmbH, announced today the closing of a collaboration agreement for the identification of typical autoantibody signatures in infectious diseases.

Biotools has recently reached an agreement with IBMP to create an epidemiological surveillance network for the Brazilian Health System, including diagnostics and production technology transfer.

Source: Biotools

Abbott (NYSE: ABT) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation’s most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.

Affymetrix, Inc. (NASDAQ:AFFX) and Signature Diagnostics AG (Signature Dx) today announced that they have signed a Powered by Affymetrix(TM) (PbA) agreement. Under the agreement, Signature Dx obtains a worldwide license to use Affymetrix(R) microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer (CRC) tests.